BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22949840)

  • 1. Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry.
    Weiland F; Fritz K; Oehler MK; Hoffmann P
    Int J Mol Sci; 2012; 13(8):9942-9958. PubMed ID: 22949840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
    Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
    Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of serum biomarkers for detection of early stage ovarian cancer.
    Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
    Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycomics analysis of serum: a potential new biomarker for ovarian cancer?
    Leiserowitz GS; Lebrilla C; Miyamoto S; An HJ; Duong H; Kirmiz C; Li B; Liu H; Lam KS
    Int J Gynecol Cancer; 2008; 18(3):470-5. PubMed ID: 17655680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.
    Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I
    Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.
    Tcherkassova J; Abramovich C; Moro R; Chen C; Schmit R; Gerber A; Moro R
    Tumour Biol; 2011 Aug; 32(4):831-8. PubMed ID: 21625941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a mass spectrometry-based assay for the ovarian cancer biomarker CA125 (MUC16) using suspension trapping (STrap).
    Schuster-Little N; Madera S; Whelan R
    Anal Bioanal Chem; 2020 Sep; 412(24):6361-6370. PubMed ID: 32215689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bead-based ELISA for validation of ovarian cancer early detection markers.
    Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of serum mesothelin in malignant and benign ovarian masses.
    Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
    Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
    Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
    Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
    Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
    J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.
    Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O
    Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies.
    Wang CW; Hanson EK; Minkoff L; Whelan RJ
    Cancer Biomark; 2023; 37(2):85-94. PubMed ID: 37248884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
    Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
    Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.